UNSPSC 51271601: Cinchocaine or dibucaine

This classification denotes an anesthetic agent with the molecular formula C20H29N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L6JW2TJG99, chemically known as 4-quinolinecarboxamide, 2-butoxy-n-(2-(diethylamino)ethyl)- but generally known as cinchocaine, which bears US NIH Compound Identifier 3025. European Medicines Agency schedules Cinchocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06287MIG. The term CINCHOCAINE is an International Non-Proprietary Name.

UNSPSC 51271601 Cinchocaine or dibucaine is a Commodity code covering local anesthetic pharmaceutical products. State and local procurement under this code encompasses generic pharmaceuticals and over-the-counter products supplied through multistate cooperative purchasing agreements, with vendors required to meet FDA compliance, current Good Manufacturing Practices (cGMP), and Drug Supply Chain Security Act (DSCSA) certification. Issuing bodies include state departments of administration and multistate cooperative purchasing alliances that aggregate procurement across participating state and local government facilities. Vendors must maintain relationships with authorized pharmaceutical wholesalers, provide comprehensive product information including National Drug Codes and packaging specifications, and demonstrate pricing flexibility through various formats (flat price, net price, or WAC-minus structures). Insurance requirements include commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (solicitation S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026. The contract term runs two years for new responders with optional extensions, with awarded vendors effective July 1, 2026. Evaluation criteria weight price competitiveness at 75 percent, with fixed pricing (10 percent), compliance with administrative fee data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must maintain at least two of three authorized wholesaler relationships (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with chargeback systems in place. The RFP does not identify specific set-aside designations or restrictions limiting responses to particular business classifications.